ESTABLISHMENT LABS HOLDINGS INC.

The company is a global medical technology enterprise dedicated to patient safety and aesthetic outcomes within the breast aesthetics and reconstruction sectors. Its primary product line comprises Motiva Implants, silicone gel-filled breast implants that feature proprietary shell, barrier, and radio-frequency identification technologies. The portfolio includes five distinct families of Motiva Implants, the Flora Tissue Expander, and minimally invasive procedural technologies such as Preservé and Mia Femtech. The business distributes its offerings directly to physicians, hospitals, and clinics, as well as through specialized third-party medical device distributors.

Commercial operations extend across more than 100 countries globally through exclusive distribution partners alongside direct sales networks in the United States, Brazil, Argentina, and multiple European nations. Field sales and clinical outreach are supported by an internal sales organization of 278 staff members and contractors. Corporate operations are organized under a parent holding company established in the British Virgin Islands, following its initial incorporation in Costa Rica.

Summary of the business section of Establishment Labs's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 1,004 employees.”